Il-Yang Pharmaceutical Invests 17.6 Billion KRW in Chinese Subsidiary for Production Base

Investment purpose: Establish factory in Chinese subsidiary (Il-Yang Pharmaceutical (Jilin)) and expand local production/sales of 'WonBidi' product
Total investment: RMB 80 million (approx. 17.6 billion KRW, 7.30% of equity)
1st phase: Cash investment of 9.9 billion KRW (RMB 45 million)
2nd phase: Reinvestment from subsidiary profits of 7.7 billion KRW (RMB 35 million)
Expected acquisition date: 2026-06-30
Subsidiary financials: Zero sales, net loss of 6.61 million KRW (operations not yet started)
Strategy: Initially import and sell as general food, then transition to local production in mid-to-long term
'WonBidi' 2023 China sales: Approx. 40.5 billion KRW (RMB 220 million)

Filing: Decision on Acquisition of Stocks and Investment Securities of Other Corporations
Company: Ilyang Pharmaceutical (007570)
Submission: Ilyang Pharmaceutical Co., Ltd.
Receipt: 05-14-2026
Under KRX KOSPI Market Division